Abbott India Peer Comparison

Abbott India Ltd. stands out in the Pharmaceuticals & Drugs sector with remarkable profitability metrics, although its growth indicators are currently stagnant. It showcases the highest ROE and ROCE among peers, making it a strong candidate despite its high valuation. Companies like Cipla and Dr. Reddy's present robust growth and valuation metrics, while others like Sun Pharma are showing signs of being overvalued due to high P/E ratios.

• • Abbott India boasts the highest ROE (37.45%) and ROCE (49.12%) among peers.
• • Cipla shows the strongest revenue growth (YoY: 13.28%) with favorable valuation metrics (PE: 23.73).
• • Sun Pharmaceutical is overvalued with a PE of 87.59 despite moderate growth metrics.

• • Abbott India Ltd.: Highest ROE (37.45%) and ROCE (49.12%) indicating strong profitability.
• • Cipla Ltd.: Strong revenue growth (YoY: 13.28%) with attractive valuation (PE: 23.73).
• • Dr. Reddy's Laboratories Ltd.: Solid revenue growth (16.54% YoY) and low PE (15.50) making it highly attractive.